TY  - JOUR
T1  - MicroRNA-224 Up-regulation: A Risk for Complications in Type 2 Diabetes Mellitus Egyptian Patients
A1  - Amal Ahmed Mohamed
A1  - Dina Mohamed Abo–Elmatty
A1  - Omnia Ezzat Esmail
A1  - Hadeer Saied Mahmoud Salim
A1  - Soha Mahmoud Abd El Salam
A1  - Amira Roshdy El-Ansary
A1  - Maha Farouk Yacoub
A1  - Sherihan Abdelrahman Ibrahim Abdelrahman
A1  - Omneya Moguib Saleh
A1  - Yosra Hassan
A1  - Eman Alhussain Abdulgawad
A1  - Yasser Sakr
A1  - Alaa Samir Wahba
JF  - Pharmacophore
JO  - Pharmacophore
SN  - 2229-5402
Y1  - 2022
VL  - 13
IS  - 6
DO  - 10.51847/SKWTZqgB22
SP  - 137
EP  - 145
N2  - Type 2 diabetes mellitus (T2DM) is a major public health concern facing the world today. Recent studies suggested that the expression of biomolecules including microRNAs especially changes during the progression of T2DM, and its related complications, and is suggestive of disease pathology. This study aimed to investigate miRNA-224 expression among T2DM Egyptian patients in addition to evaluating its relationship to diabetic complications. A total of 205 individuals were subjected to this case-control study, cases were allocated to 100 T2DM patients and 105 healthy ones. The biochemical, anthropometric, psychometric parameters and miRNA-224 expression by Real-time PCR technique were measured. T2DM patients had significantly elevated levels of glycated hemoglobin (HbA1C), fasting blood suger (FBS), post prandial blood sugar (PPBS), international normalization ratio (INR), creatinine, urea, cholesterol, triglyceride (TG) and low density lipoproteins (LDL) and significantly decreased high density lipoprotein (HDL) compared to healthy subjects. MiRNA-224 expression was significantly upregulated in T2DM patients compared to healthy individuals p (
UR  - https://pharmacophorejournal.com/article/microrna-224-up-regulation-a-risk-for-complications-in-type-2-diabetes-mellitus-egyptian-patients-myto4kid4psthyx
ER  -